FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077882848> ?p ?o ?g. }

• W2077882848 endingPage "3908" @default.
• W2077882848 startingPage "3896" @default.
• W2077882848 abstract "To determine the safety and efficacy of additional courses of rituximab in patients with rheumatoid arthritis (RA).An open-label extension analysis of RA patients previously treated with rituximab was conducted. Patients who had participated in any of 3 double-blind trials were eligible for additional courses (2 infusions of 1,000 mg given 2 weeks apart) if they exhibited a swollen joint count and tender joint count of > or =8 with > or =16 weeks elapsing after the previous course. Safety was assessed in patients receiving all or a portion of a rituximab course. Efficacy was assessed 24 weeks after each course, using the American College of Rheumatology 20% criteria for improvement (ACR20), ACR50, ACR70, European League Against Rheumatism (EULAR) response criteria, Disease Activity Score in 28 joints, the disability index of the Health Assessment Questionnaire, and Short Form 36 scores, stratified according to prior tumor necrosis factor (TNF) inhibitor exposure.A total of 1,039 patients received > or =1 course of rituximab. Of these, 570 received 2 courses, 191 received 3 courses, and 40 received 4 courses, for a total of 1,669 patient-years. Irrespective of prior TNF inhibitor exposure, ACR20 responses were comparable at week 24 after course 1 and at week 24 after course 2 (65% versus 72%), as were ACR50 and ACR70 responses. EULAR moderate/good responses were also comparable in course 2 relative to course 1 (88% versus 79%), with EULAR remission occurring in a 2-fold higher proportion of patients after course 2 than after course 1 (13% versus 6%). The most common adverse events, which were mild-to-moderate acute infusion-related events, decreased with each course. The serious infection rate after course 1 (5.1 per 100 patient-years) remained stable through additional courses. The proportion of patients with circulating IgM and IgG levels below the lower limit of normal (LLN) increased with subsequent courses; however, serious infection rates in these patients (5.6 per 100 patient-years in patients with low IgM levels and 4.8 per 100 patient-years in patients with low IgG levels were comparable with those in patients with immunoglobulin levels above the LLN (4.7 per 100 patient-years). Patients with human antichimeric antibody (9.2%) did not exhibit decreasing efficacy or present additional safety concerns.These findings indicate that patients treated with repeated courses of rituximab have sustained clinical responses with no new adverse events." @default.
• W2077882848 created "2016-06-24" @default.
• W2077882848 creator A5013663765 @default.
• W2077882848 creator A5015083124 @default.
• W2077882848 creator A5018678002 @default.
• W2077882848 creator A5023265561 @default.
• W2077882848 creator A5026326762 @default.
• W2077882848 creator A5041839845 @default.
• W2077882848 creator A5042617054 @default.
• W2077882848 creator A5046261111 @default.
• W2077882848 creator A5052078671 @default.
• W2077882848 creator A5063158209 @default.
• W2077882848 creator A5064870612 @default.
• W2077882848 creator A5072072222 @default.
• W2077882848 creator A5077099389 @default.
• W2077882848 creator A5080646462 @default.
• W2077882848 creator A5083881582 @default.
• W2077882848 date "2007-12-01" @default.
• W2077882848 modified "2023-10-15" @default.
• W2077882848 title "Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis" @default.
• W2077882848 cites W1526039364 @default.
• W2077882848 cites W1685882185 @default.
• W2077882848 cites W1973683306 @default.
• W2077882848 cites W1977206110 @default.
• W2077882848 cites W1979364075 @default.
• W2077882848 cites W1980827798 @default.
• W2077882848 cites W1985004174 @default.
• W2077882848 cites W1995228104 @default.
• W2077882848 cites W1995386393 @default.
• W2077882848 cites W2000905503 @default.
• W2077882848 cites W2024644107 @default.
• W2077882848 cites W2031092466 @default.
• W2077882848 cites W2046549669 @default.
• W2077882848 cites W2063791317 @default.
• W2077882848 cites W2077158310 @default.
• W2077882848 cites W2099184704 @default.
• W2077882848 cites W2110177517 @default.
• W2077882848 cites W2115008314 @default.
• W2077882848 cites W2118994799 @default.
• W2077882848 cites W2123408911 @default.
• W2077882848 cites W2128402413 @default.
• W2077882848 cites W2157130851 @default.
• W2077882848 cites W2159106700 @default.
• W2077882848 cites W2165404431 @default.
• W2077882848 cites W2314052274 @default.
• W2077882848 cites W2319957449 @default.
• W2077882848 cites W2336588424 @default.
• W2077882848 cites W2496298205 @default.
• W2077882848 cites W27919971 @default.
• W2077882848 cites W42365668 @default.
• W2077882848 cites W4292806894 @default.
• W2077882848 cites W60759546 @default.
• W2077882848 doi "https://doi.org/10.1002/art.23059" @default.
• W2077882848 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18050221" @default.
• W2077882848 hasPublicationYear "2007" @default.
• W2077882848 type Work @default.
• W2077882848 sameAs 2077882848 @default.
• W2077882848 citedByCount "302" @default.
• W2077882848 countsByYear W20778828482012 @default.
• W2077882848 countsByYear W20778828482013 @default.
• W2077882848 countsByYear W20778828482014 @default.
• W2077882848 countsByYear W20778828482015 @default.
• W2077882848 countsByYear W20778828482016 @default.
• W2077882848 countsByYear W20778828482017 @default.
• W2077882848 countsByYear W20778828482018 @default.
• W2077882848 countsByYear W20778828482019 @default.
• W2077882848 countsByYear W20778828482020 @default.
• W2077882848 countsByYear W20778828482021 @default.
• W2077882848 countsByYear W20778828482022 @default.
• W2077882848 countsByYear W20778828482023 @default.
• W2077882848 crossrefType "journal-article" @default.
• W2077882848 hasAuthorship W2077882848A5013663765 @default.
• W2077882848 hasAuthorship W2077882848A5015083124 @default.
• W2077882848 hasAuthorship W2077882848A5018678002 @default.
• W2077882848 hasAuthorship W2077882848A5023265561 @default.
• W2077882848 hasAuthorship W2077882848A5026326762 @default.
• W2077882848 hasAuthorship W2077882848A5041839845 @default.
• W2077882848 hasAuthorship W2077882848A5042617054 @default.
• W2077882848 hasAuthorship W2077882848A5046261111 @default.
• W2077882848 hasAuthorship W2077882848A5052078671 @default.
• W2077882848 hasAuthorship W2077882848A5063158209 @default.
• W2077882848 hasAuthorship W2077882848A5064870612 @default.
• W2077882848 hasAuthorship W2077882848A5072072222 @default.
• W2077882848 hasAuthorship W2077882848A5077099389 @default.
• W2077882848 hasAuthorship W2077882848A5080646462 @default.
• W2077882848 hasAuthorship W2077882848A5083881582 @default.
• W2077882848 hasBestOaLocation W20778828481 @default.
• W2077882848 hasConcept C126322002 @default.
• W2077882848 hasConcept C141071460 @default.
• W2077882848 hasConcept C1862650 @default.
• W2077882848 hasConcept C198451711 @default.
• W2077882848 hasConcept C2777489490 @default.
• W2077882848 hasConcept C2777575956 @default.
• W2077882848 hasConcept C2779338263 @default.
• W2077882848 hasConcept C2780653079 @default.
• W2077882848 hasConcept C71924100 @default.
• W2077882848 hasConceptScore W2077882848C126322002 @default.
• W2077882848 hasConceptScore W2077882848C141071460 @default.

• next